How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Interventional procedure overview of percutaneous transluminal renal sympathetic denervation for resistant hypertension

    Closed for comments This consultation ended on at   Request commenting lead permission

    References

    1. Pisano A, Lannone LF, Leo A et al. (2017) Renal denervation for resistant hypertension. Cochrane database of systematic reviews 11: CD011499

    2. Townsend RR, Walton A, Hettrick DA et al. (2020) Incidence of renal artery damage following percutaneous renal denervation with radio frequency renal artery ablation systems: Review and Meta-Analysis of published reports. EuroIntervention Jaa-728 2020, doi: 10.4244/EIJ-D-19-00902

    3. Fengler K, Rommel KP, Blazek S et al. (2019) A three-arm randomized trial of different renal denervation devices and techniques in patients with resistant hypertension (RADIOSOUND-HTN). Circulation 139(5): 590-600

    4. Kario K, Yokoi Y, Okamura K et al. (2022) Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. Hypertension research: official journal of the Japanese Society of Hypertension 45(2): 221-31

    5. Azizi M, Sanghvi K, Saxena M et al. (2021) Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet (London, England) 397(10293): 2476-86

    6. Mahfoud F, Bohm M, Schmieder R et al. (2019) Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. European Heart Journal 40(42): 3474-82

    7. Zweiker D, Lambert T, Steinwender C et al. (2016) Effects of renal denervation documented in the Austrian national multicentre renal denervation registry. PloS one 11(8): e0161250

    8. Sharp ASP, Davies JE, Lobo MD et al. (2016) Renal artery sympathetic denervation: observations from the UK experience. Clinical research in cardiology: official journal of the German Cardiac Society 105(6): 544-52

    9. Fengler K, Reimann P, Rommel KP et al. (2021) Comparison of long-term outcomes for responders versus non-responders following renal denervation in resistant hypertension. Journal of the American Heart Association 10(21): e022429

    10. Lobo MD, Sharp ASP, Kapil V et al. (2019) Joint UK societies' 2019 consensus statement on renal denervation. Heart 105: 1456-63

    11. Schmieder RE, Mahfoud F, Mancia G et al. (2021) European Society of Hypertension position paper on renal denervation 2021. Journal of Hypertension, 39(9), 1733-41.

    12. Williams B, Mancia G, Spiering W et al. (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal 39: 3021-104

    13. Denolle T, Chamontin B, Doll G et al. (2016) Management of resistant hypertension: expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology. Journal of Human Hypertension 30: 657-663